Dose Escalating Study of BPI-3016 in Healthy Subjects
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled, dose finding study evaluating the
safety, pharmacokinetics and pharmacodynamics of subcutaneously injected BPI-3016 in Chinese
healthy subjects.